A-349821 | 372513-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: A-349821
• 英文别名: 4-[(4'-{3-[(2R,5R)-2,5-dimethylpyrrolidinyl]propoxy}[1,1'-biphenyl]-4-yl)carbonyl]morpholine；A-349821 free base；[4-[4-[3-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]propoxy]phenyl]phenyl]-morpholin-4-ylmethanone
• CAS: 372513-99-0
• 化学式: C₂₆H₃₄N₂O₃
• 分子量: 422.568
• InChiKey: CFUHKRLMDNFZED-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-羟基-[1,1-联苯]-4-羧酸甲酯 在 lithium hydroxide 、 氯化亚砜 、 potassium carbonate 、 N,N-二异丙基乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 丁酮 为溶剂， 反应 100.0h， 生成 A-349821
  参考文献：
  名称：

  Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists

  摘要：

  Novel 4'-[(NRIR2-1-yl)]-propoxy-biaryl-4-carboxamides were designed and synthesized. All compounds were tested for affinity at histamine H(3)receptors. Most compounds were highly potent and selective for human and rat H-3 receptors and selected examples such as A-349821 showed functional antagonism of H3 receptors in vitro and in a mouse dipsogenia model. (C) 2003 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(03)00118-5

文献信息

• ENZYME INHIBITORS
  申请人：Thormann Michael

  公开号：US20070244177A1

  公开（公告）日：2007-10-18

  There is dislosed herein compounds of formula (I), wherein: R 1 , R 2 , R 3 , R 4 and R 5 are defined throughout the description and the claims. The compounds of formula (I) are useful for the treatment of neurological diseases and neurodegenerative diseases, e.g. anxiety, depression, Alzheimer's disease etc.

  本文披露了公式（I）的化合物，其中：R1、R2、R3、R4和R5在描述和权利要求中有定义。公式（I）的化合物可用于治疗神经疾病和神经退行性疾病，例如焦虑、抑郁、阿尔茨海默病等。
• Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
  申请人：——

  公开号：US20020111340A1

  公开（公告）日：2002-08-15

  Compounds of formula (I) 1 are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands.

  化学式为(I)1的化合物可用于治疗由组胺-3受体配体预防或改善的疾病或症状。
• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Probiodrug AG

  公开号：EP1713780B1

  公开（公告）日：2012-01-18
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• US6316475B1
  申请人：——

  公开号：US6316475B1

  公开（公告）日：2001-11-13